Texas Retina Associates

All Texas Retina Associates?offices will be closed Thursday, November 28, and Friday, November 29, for the Thanksgiving holiday. During this time of reflection and gratitude, we want you to know how thankful we are for YOU!?From our family to yours, we wish you a Happy Thanksgiving!

Today is the Great American Smokeout. Smoking remains the single largest cause of preventable disease and premature death in the United States. You probably know that smoking increases your risk of developing heart disease, stroke and cancer. Did you know it can also harm your eye health and vision? Learn more in our latest blog:?https://lnkd.in/eDjp-HWi

Our own Dr. Coors recently enrolled and treated the first patient in the Phase III DAYBREAK trial evaluating an intravitreal tarcocimab tedromer and tabirafusp tedromer compared with intravitreal aflibercept in participants with neovascular (wet) age-related macular degeneration. Dr. Coors serves as a Principal Investigator for this clinical trial in our Plano office, Dr. Solley in our Arlington office and Dr. Williams in our Fort Worth office. Learn more: https://lnkd.in/envvjyYt

Today we’re thankful for this recent feedback about Dr. Timothy Fuller. In addition to providing medical retina care, he sub-specializes in treating ocular melanoma and trained under international ocular cancer research and treatment leaders Jerry A. Shields, MD, and Carol Shields, MD, at Wills Eye Hospital in Philadelphia, Pennsylvania. Dr. Timothy Fuller cares for patients in our Dallas Main and Athens offices. He shares how Texas Retina cares for our ocular melanoma patients in this video:?https://lnkd.in/eFZndi-9

November is National Family Caregivers Month. At Texas Retina, we recognize and thank all of the humble, unsung heroes who selflessly give of their own time and energy to care for family members, friends and neighbors. “Caregiving often calls us to lean into love we didn’t know possible.” – Tia Walker

On behalf of everyone at Texas Retina Associates, we would like to extend our deepest gratitude for the sacrifices that our service members, both past and present, have made for our country.?

We’re excited to announce that our new, larger Wichita Falls office is officially open! Dr. Laura and our Wichita Falls team began seeing patients there on November 7. Dr. Fish, Dr. Solley and Dr. McClellan will also serve patients in this new location. At 7,500 square feet, the new Wichita Falls office is twice the size of our previous one and will allow us to better serve our patients in this growing community. Learn more: https://lnkd.in/eyNrBkVK

Dr. Abbey recently presented “Innovation in Retina for the ASC” at the Outpatient Ophthalmic Surgery Society (OOSS) Symposium 2024. He highlighted the advantages and disadvantages of several recent surgical advancements in the field of retina, including intraoperative optical coherence tomography (iOCT), 3D visualization, gene therapy, the port delivery system (PDS), and encapsulated cell therapy (ECT). Learn more in our latest blog:?https://lnkd.in/ebKv5YWG

Diabetes damages blood vessels all over the body, including in the eye. This can lead to conditions like diabetic retinopathy and diabetic macular edema. However, the good news is that about 90% of vision loss from diabetes can be prevented. In our latest blog, we explain more about diabetic eye disease and share 6 steps people can take to help protect their eyes and vision: https://lnkd.in/ejRnBS4X

Our own Dr. Abbey became the first to dose a patient in the Phase III LUGANO clinical trial of Duravyu for the treatment of wet age-related macular degeneration (AMD). Duravyu is an investigational sustained delivery maintenance treatment for wet AMD that combines vorolanib, a selective tyrosine kinase (anti-VEGF) inhibitor, with bioerodible Durasert E?.??Dr. Abbey serves as a Principal Investigator for this trial in our Dallas Main office, and Dr. Coors is a Principal Investigator in our Plano office. Learn more:?https://lnkd.in/eqGZshGA